"rationale","id","versionIdentifier","uuid:ID","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2","cee05b5c-c7f3-4c0c-9c6c-cf0f4985a24f","StudyVersion"
